Key points from article :
A £1 million Innovate UK grant will fund the AI-VISION project, a collaboration between Durham University, The Institute of Cancer Research, The Royal Marsden Hospital, and Concr.
Their mission is to personalise cancer treatment for patients with early triple negative breast cancer.
This can be done by analysing tissue samples to identify biomarkers that predict response to chemotherapy, with or without immunotherapy.
This project is groundbreaking because currently, doctors don't have a way to link a patient's genes to their likely response to specific treatments.
Using Concr's FarrSight® platform, AI-VISION will link genomic data to clinical data for the first time, creating a tool for doctors to predict how individual patients will respond to different treatment options.
This has the potential to: 1) personalise cancer treatment for better outcomes and 2) accelerate the development of new, more effective therapies.
The project is already underway, analysing tissue samples and building the data platform.
